Homeopathic medicinal product having stress-protective and growth-stimulating effect, regulating metabolism in young farm animals and poultry

FIELD: veterinary medicine.

SUBSTANCE: product comprises Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the dilutions described below in the following ratio, in parts: Lycopodium clavatum ⌀=D1 0.004, Podophyllum peltatum ⌀ 0.003, Acidum arsenicosum ⌀=D2 0.0001, Phosphorus ⌀=D3 0.001, Thuja occidentalis ⌀ 30, Echinacea purpurea ⌀ 30, Silybum marianum ⌀ 60, Selenocysteine 0.2.

EFFECT: product has an effective stress-protective and growth-stimulating effect, it regulates the metabolism in young farm animals.

3 cl, 10 tbl, 1 ex

 

The invention relates to veterinary, namely to homeopathic medicinal products for veterinary use, providing stressreduction and growth-promoting effect, regulating metabolism in young farm animals and poultry.

In conditions of industrial livestock and poultry on the organism of animals and birds are constantly exposed to the stressors chemical, physical, biological, technological and feed origin, depressing the immune reactivity of the organism and leading to the development of secondary immune deficiencies that have a negative impact on metabolism and liver function.

Many researchers (Horizons P. D., 1979; Plamenco S. I., 1991; Sidorov, V. T., 1983; Sokolov, V. D., 2000, etc.) found that under stress, despite the protective reaction of the organism, there are destructive processes in the organs and tissues, which take place according to the type of inflammatory and allergic reactions, particularly in the intestine and lymphoid tissue. When you consider that in the first hours of life of the animal, hitting completely the other conditions subject to strong stress effects as the birth process is stressful, destructive processes in the body greatly reduce its life force.

The result is increased morbidity and reduced average daily weight gain and �ahranot livestock, elongate and dorogaya medication regimens, increased use of fodder (Evtimov I. A., 2004).

Known "Method of prevention and correction of transport stress in cattle" (patent RU 2160533. The method involves feeding animals with feed licorice in the amount of 3.0 g/kg of body weight per day for 8 days before shipping. The method allows to stimulate the immune resistance of the body, normalize neuromuscular excitation, to constrain the mobilization of energetic substances, which leads to the reduction of losses of meat productivity of cattle during transport stress. However, this method is not applicable for the correction of technological stress in poultry and pig production.

The closest technical solution is the ETL tool-Se-composition (number of registration certificate of the Russian Federation 32-2-11.7-3073 PVR-2-11.7/02322), which has hepatoprotective, antispasmodic, anti-inflammatory properties. Activating the metabolism, has a regulating effect on protein, carbohydrate, fat, mineral, vitamin metabolism and the body's immune system, helps to enhance the resistance of animals to infectious diseases and adverse environmental factors, improves motor skills zheludochno�the gastrointestinal tract.

Based on the indications for use stated in the instructions for use, and data provided in the following sources: "the Method of prevention of gastrointestinal diseases in calves" (patent RF 2313951), "a Method for prevention of gastro-intestinal diseases in mink and correction of their natural resistance of the organism" (RF application 2008147519), "a Method of increasing the safety and productivity of pullets chickens" (patent RF 2392950), ETL-Se-the composition is administered to young farm animals, poultry and fur animals for the prevention of gastrointestinal and respiratory diseases of various etiologies, caused by an abrupt change of diet, weaning, regrouping, transport, or unfavorable environmental factors. ETL-Se-composition reduces the incidence of gastro-intestinal tract in young farm animals, increases their average daily weight gain and reduces costs for the treatment of gastrointestinal diseases, helps accelerate the formation of microflora in the gut of healthy calves, increases the natural resistance of the organism, increases the safety and productivity of chickens, enhances the immune response during vaccination. However, this tool has not stressreduction properties.

The object of the present invention is to provide domestic homeopaticos�th medicines which has simultaneously stressreduction and growth promoting action and regulating metabolism in young farm animals and poultry.

The task is achieved by the fact that the proposed homeopathic remedy with stressreduction and growth-promoting effect, regulating metabolism in young farm animals and poultry, characterized by the fact that it contains Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the following dilutions in the following ratio, in parts:

Lycopodium clavatum ⌀=D10,004
Podophyllum peltatum ⌀0,003
Acidum arsenicosum ⌀=D20,0001
Phosphorus ⌀=D30,001
Thuja occidentalis ⌀30
Echinacea purpurea ⌀30
Silybum marianum ⌀60
Selenocysteine0,2

The technical result obtained when using the present and�gaining, is to expand the Arsenal of homeopathic remedies, with stressreduction and growth-promoting effect, regulating metabolism in young farm animals and poultry.

The proposed tool can be made in the form of oral solution and microcapsules. All included in the inventive composition components known in homeopathy and allowed in medical and veterinary practice in Germany (Homeopathic Pharmacopoeia 1985) and in Russia (PVR 2.06.0290-96 20.02.97).

The invention is illustrated by the following example.

Example 1:

Composition per 1000 liters of solution for oral use:

Lycopodium clavatum ⌀=D14 µl
Podophyllum peltatum ⌀3 µl
Acidum arsenicosum ⌀=D20.1 µl
Phosphorus ⌀=D31 µl
Thuja occidentalis ⌀30 ml
Echinacea purpurea ⌀30 ml
Silybum marianum ⌀60 ml
Selenocysteine0.2 mg
Ethyl alcohol� 96% 93,8 l
Purified waterup to 1000 l

The required number of components selected by microspace, to measure the use of large amounts of measured ware first class precision. A measured amount of the components is placed into a measuring utensils shall be submitted ethyl alcohol 96% (ethanol GOST 5962) to 1 liter, stirred, placed in the reaction vessel, where is added the remaining amount of ethyl alcohol 96% and brought the purified water to 1000 liters.

Any change in the qualitative composition of the proposed tools, and changing the ratio of the components does not lead to the achievement of the claimed technical result.

The claimed means in the form of microcapsules prepared as follows: the required number of components selected by microspace, to measure the use of large amounts of measured ware first class precision. A measured amount of the components is placed into a measuring utensils shall be submitted ethyl alcohol 96% (ethanol GOST 5962) to 100 ml, then the prepared solution is mixed with the reaction mixture of stearates and ultrarrepublicanos get install microcapsules of not more than 1 mm.

Study of specific activity of the claimed funds in livestock farms and specialized scientific�research institutions of Russia (as a comparison drug in a number of cases the drug was used ETL-Se-composition).

1. The study stressreduction properties of the claimed funds

The simulated stress were carried out on the basis of the Kostroma GSHL 60 chickens 8 weeks of age, breed "Lohmann brown" by southalabama.

Chickens were divided on the basis of pairs of analogues of 3 groups of 15 Chicks each. The Chicks of the 1st experimental group were asked by the claimed means in the dose of 0.02 ml/goal., the required amount of the stated means designed for all the animals of the 1st experimental group were added to the troughs with water. The country funds were started 3 days before cathelineau and for 3 days after it. Chickens of the 2nd experimental group asked the drug ETL-Se-composition tool at a dose of 0.02 ml/goal., required quantity of this drug, designed for all livestock 2nd experimental group were added to the troughs with water. The country funds were started 3 days before cathelineau and for 3 days after it. Chickens of the control group was used. All groups of chickens were subjected to sothelioma, which was performed for 1 hour with an amplitude of 4 cm and a frequency of 75 oscillations per minute.

In the process, was estimated dynamics of the General clinical and biochemical blood indices, the dynamics of changes in body mass of chickens. Data on dynamics of clinical and biochemical blood parameters are presented in table 1.

Analyzing the data of table 1, it is clear that PR� stress for all chicken has been a significant increase in the content of erythrocytes and hemoglobin, when reducing the color index. So, 3 hours after cathelineau the amount of hemoglobin in control chickens increased by 5.1%, which is 1.5% higher than in the 2nd experimental group and 3.3% higher than in the first experimental group. On the third day, the concentration of hemoglobin in control and the 2nd experimental group was higher (12.3% and 6.8% above background values), whereas in the 1st experimental group, this indicator decreased and practically did not exceed background (+0,6%). Thus after 3 hours after stressaway there was a sharp decrease of the color index by 5.1% in the control group, 1.2% in the 1st experimental group and 6.4% in the 2nd experimental group. On the third day of this indicator slightly increased in the control and 2-nd experimental group and was below the background data of 3.8% and 2.5% respectively. In the 1st experimental group, the color indicator has recovered and were within the physiological norm. When determining the erythrocyte sedimentation rate revealed her sharp increase of 130% in the control group, 70% in the experimental group and by 120% in the 2nd experimental group after 3 hours after stressaway. On the 3rd day of this ratio decreased and exceeded the background data on the 110% in the control group, 10% in the 1st experimental group and 70% in the 2nd experimental group. Such changes can be explained by increased body temperature, rapid pulse and breathing, increased defecation in C�of plat, subjected to stress, the result of which was thickening of the blood and its concentration. The smallest changes were observed in the 1st experimental group, which suggests that the inventive tool allows you to preserve the stability of the blood and consistency in the composition and the total number of vascular blood. There was a sharp decrease of the number of common protein in the blood of the chickens of the control group after 3 hours 23.9%, while on the 3 day of the experiment, this rate was reduced by 15.3% on 3rd day after stressaway, remaining expressed by 20.9%. Such a sharp decrease in the concentration of total protein after stressaway can talk about the violation of protein generating functions of the liver as a reaction to stress. In the 2nd experimental group picture of the decrease of total protein was not expressed: so, 3 hours after stressaway decrease in total protein was 14.8%, but after 3 days the total protein concentration increased and was lower than baseline rates of 2.75%. A different picture was in chickens of the experimental group. With the introduction of the stated means 3 hours after stress showed a slight decrease in the concentration of total protein (4.9%), while on the 3 day experience instead of decreasing has increased the total protein content of 21.5%, which indicates an increase belkovosvazavatei liver function. 3 hours after stressaway in in�ex groups showed an increase in the concentration of glucose in the blood: by 36.1% in the control group, 27.8% in the 1st experimental group, 29.5% in the 2nd experimental group. This suggests that under the action of stress factors observed intense release of glucose in the blood as a result of mobilization of the catecholamine breakdown of liver glycogen. On the 3rd day of the experiment there was a marked decline of glucose in the control group, was similarly decreased by 27.8% and 9.8% in the 2nd experimental group, which indicates a deterioration of carbohydrate metabolism in the organism of chickens. This may be associated with increased consumption of glycogen and increased combustion of glucose, which goes to the restoration of the energy supply in the body. In chickens, the 1st experimental group on day 3 after stressaway the concentration of glucose was increased by 1.6% relative to baseline rates, which suggests that the claimed means normalizes carbohydrate metabolism chickens under stress.

As a result of the impact of stress in chickens of the control group registered a decrease in body weight of 1.7%, while in the 1st experimental group increased body mass by 2.3% (15,7 g), in the 2nd group body weight in chickens has not practically changed (increased by 1.6 g), data are presented in table 2.

Thus, when experimental transport stress in chickens caused by using Southall device in their body after stress there is a marked change of metabolism and re�some reduction in body weight.

Prophylactic administration declared unit helps to maintain the stability of the blood and consistency in the composition and the total number of vascular blood, promotes faster recovery of protein and carbohydrate metabolism and live weight in stressed animals, which confirms stressreduction properties of the claimed funds. Stressreduction properties of the drug comparison ETL-Se-the composition is almost not expressed.

2. Growth stimulating properties of the claimed funds

Growth stimulating effect of the drug was studied on the basis of the Kostroma state agricultural Academy. On the principle of analogues were formed three groups of broiler chickens ROSS 308 parent at the age of 15 days, the average weight 345,8 g, two experimental and one control 20 animals each. In the 1st experimental group chickens orally applied drug ETL-Se composition in a dose of 0.02 ml/goal., 1 time a day, for 20 days. The drug was administered with water 15 days before slaughter age (35 days) chickens daily. In the 2nd experimental group chickens orally applied the claimed means in the dose of 0.02 ml/goal., 1 time a day, for 20 days. As the drug ETL-Se composition, and claimed the tool was used with water 15 days before slaughter age (35 days) chickens daily. Chickens of the control group were intact.

The country declared funds and drug ETL-S composition is performed as follows. A day before the application of funds determined volume of water, drink the chicken for 2 hours, the required amount of funds claimed and drug ETL-Se-composition corresponding to the number of chickens group, bred in the prescribed volume of water and poured and pre-washed without the use of disinfectants drinkers, for each group separately. The number of drinkers were given free access to the drug all the chickens of the group.

The study of the dynamics of live weight of broiler chickens showed a stable increase of the studied parameters in experimental and control groups (table.3).

The live weight of experimental chickens from 15 to 35 day increased to 4.16 times in the 1st experimental group; 4.29 times in the 2nd test and 4.01 times in control. At the end of the growth of young birds 2nd experimental group by the value of the studied parameter exceeded - to 80.8 g (5.3%) chickens of the control group and 32 g (2,1%) chickens of the 1st experimental group.

The feeding of the claimed funds to the broilers had a positive effect on final live weight of broilers, the result presented in table 3. A similar trend was observed for average daily gain (table 4).

This rate of Chicks studied groups with age increased. With 15 days until the final stage of growth average daily gain of chickens of the 2nd experimental group was higher than that record� in chickens the other groups and amounted to 58,4 g, in the 1st experimental group, the average daily weight gain was 1.7 g (2.9%) in the control group, average daily gain was lower 4.34 g (7.4%).

Summarizing data on the growth of body weight of broiler chickens, it was found that the bird of the 2nd test group receiving the stated means, characterized by greater intensity of growth during the whole growing period in comparison with the other groups. The drug ETL-Se-song also had a growth stimulating effect, but it was less pronounced than in the application of the claimed funds.

These data were confirmed by the dynamics of morphological and biochemical blood indices, presented in table 5. The data of table 5 shows that the highest value of hemoglobin observed in the 2nd experimental group, where his number was 10,70 g/%, 9.7% (or 0.95 g/%) more than in the beginning of the experiment (background) (P<0.05) and 0.45 g/% (4.4%) of the rate in the control group. In the blood of the 1st experimental group of chickens hemoglobin reached is 10.68 g/%, 8.9%, or 0.87 g/% compared with its value at the beginning of the experiment. The comparison with the control also shows the advantage of experimental birds 0.43 g/%, i.e. 4.2%. In the 2nd experimental group was more than the total of red blood cells - 3,18±0,05 million, which is higher than the background rate of 1.46 million From the same table shows that the morphological parameters of blood of Cipla� 1st and 2nd experimental groups had an advantage in these blood parameters. The greatest amount of total protein was in chickens of the 2nd experimental group, where his number was 5,59±0.42 g/%. This value by 18.9% (or 0.89 g/%) more than in the beginning of the experiment and 3.1% (or 0.17 g/%) value of control. The content of total protein in blood of chickens of the 1st experimental group was equal to 5.58±0,53 g/%, which is higher than the background rate of 0,81 g/% (16.9%) and more control at 0.16 g/% (or 2,95%).

Thus, the level of total protein in the serum of chickens studied groups as they get older tended to increase towards the end of the experiment in comparison with baseline in the control group 4.75±0.31 to 5,42±0.45 g/%. Therefore, when growing chickens using published tools and drug ETL-Se-composition is an increase in total serum protein, and in the application of the stated means these changes are more pronounced.

At 35 days of age) pre-slaughter weight of chickens in the 1st experimental group amounted to 1491,6 g, 48.8 g is higher than in the control group (3,38%). Pre-slaughter weight of chickens in the 2nd experimental group amounted to 1523,6 g, to 80.8 g is higher than in the control group (5.6 percent). Pre-slaughter weight of chickens in the 2nd experimental group was also higher than that of chickens 1st experimental group of 32 grams or 2.15 per cent. Slaughter yield was also higher in chickens of the 2nd experimental group of 80.2%, which is 2.3% higher than in the control group, �and 1% higher than in the 1st experimental group.

Thus, it is found that the claimed tool effectively restores the main clinical and biochemical indicators of blood and has a much more pronounced growth-stimulating properties than the drug ETL-Se-song. Such zootechnical indices in broiler chickens, as pre-slaughter carcass weight, weight of eviscerated carcass, carcass yield, were higher than in intact chickens and using the drug ETL-Se-song.

3. The influence of the claimed funds for the growth and development of calves

The effectiveness of the claimed tools researched on the base of LLC "Agrofirma Kameshkovsky" Vladimir region. In the beginning of the experiment on the principle of analogues were selected 2 groups of calves of black-motley breed at the age of 3-4 days with symptoms antenatally malnutrition 1-2 degrees in the experimental group consisted of 27 calves in the control 28. The calves in the 1st experimental group was administered the claimed remedy oral 1 ml of 1 times a day for 14 days. Calves 2nd group treatment and preventive measures were carried out according to the scheme of the economy.

Evaluation criteria: the General condition, the dynamics of biochemical indices (at the beginning of the experiment and at the end), the incidence in the period of the study, average daily weight gain.

In daily inspection, it was noted that the calves of the experimental group more active, better appetite. The result� of application of the claimed means are presented in table 7.

Only the experimental group dyspepsia was registered in 8 (29,6%) calves, while in the control group, the disease occurred in 21 (75%) of a calf, which is 2.6 times higher than in the experimental group. During the first 30 days of life respiratory diseases ill 4 calf from the experimental group (14,8%) and 10 calves from the control group (35.7 percent), 20.0% higher than in experienced. The safety in the control group was 10.6% lower than in experienced.

Dynamics of average daily live weight gain was also higher in the experimental group. In average, an average daily gain of calves in the experimental group was 104,3 g more than the control (the 662.5±31,1 and 558,2±28,9* p≤0.05, respectively). In the analysis of blood biochemical parameters showed a difference between the calves of the control and experimental groups, the data presented in table 8.

Before the application of the stated means of biochemical parameters in control and experimental groups were not significantly different. Upon completion of the course of the drug in the experimental group reported higher total protein to 70,04±2,871, while in the control group, the total protein level dropped to 53,01±3,095, which is below the limits of the rules. In both groups at the beginning of the experiment had impaired the ratio of calcium and phosphorus (1.4 in the control group, experienced 1.65 V), but by the end of the experiment in the experimental group there was recovery of this index to 1.33, BP�kitchen as in the control group it increased to 1.76. In all groups at the beginning of the work noted an increase in the activity of aminotransferases, however, their ratio (coefficient De Rytis) in the experimental group began to recover by the end of the experience. It should be emphasized that the indicators of liver function (total bilirubin, ALT, AST) in animals of all groups remained within the normal range. The level of glucose in the blood of the calves in the control group was significantly increased during the study to 4,58±0,398, far exceeding the limit of the rules. In the experimental group initially, the glucose level was slightly below normal (3,03±0,090), but after the course increased to normal values (3,51±0,306). Differences according to the level of carotene in the blood between the groups were observed.

Thus, the inventive tool provides corrective action for the main biochemical indicators of blood, helps to restore protein, carbohydrate and mineral metabolism, has a growth stimulating effect, resulting in improving the safety and average daily gain of calves, decline in milk period.

4. The influence of the claimed funds for the growth and development of calves during the fattening period

The work was carried out in ZAO Carotino" Vladimir region. For work was selected by an experienced group of 20 calves at the age of 50-60 days. The results were compared with the same indicators in rear� - filled group which was a group of calves (20 goal). Calves were selected to the group on the principle of analogues, the ratio of steers and heifers in both groups were 50%/50%. Both groups contained in one calf house in the neighbouring paddocks, feeding the same.

The calves of the experimental group in the water for drinking was added to the stated means the rate of 2,0 ml per head per day for 14 days. Calves of the control group stated the tool is not used.

Criteria for evaluation efficacy: the overall condition, average daily weight gain, disease, safety.

During the inspection of the animals of the experimental group in the period of the work of deviations from the norms of development was observed. Calves of the experimental group visually looked better, more active, shiny coat.

The results are presented in table 9.

In the experimental group (the use of the claimed funds) average daily gain in calves in the group, on average 818,7±54,6 g (in steers 858,6 g, heifers 768,9 g), whereas in the control group, the weight gain was on average 718,5±37,6 g (in steers 745,6 g, heifers 691,3 g).

Thus, the inventive tool has a marked stimulating effect on the growth and development of calves.

4. The study stressreduction steps of the claimed means in deuterocohnia Chicks

Work on the study stressreducing action asserted environments�TWA when deuterocohnia chickens were conducted in JSC "Vladzernoprodukt". Stressreduction properties of the claimed means was evaluated by deuterocohnia chickens at the age of 30 days. For the experiment was created with regard to the principle of analogues of 3 groups of chickens, 300 animals each.

The procedure of beak trimming chickens was conducted at 30 days of age. 7 days before the beak trimming procedure and within 7 days after the procedure of beak trimming chickens 1st experimental group in the system of medication in the water added to the claimed means in the dosage of 2 ml/100 birds Chicks. In the second group 7 days before the beak trimming procedure and within 7 days after the procedure of beak trimming in the system of medication added drug ETL-Se-the composition is in a dosage of 2 ml/100 birds Chicks. In the control group, no special preparations when deuterocohnia not introduced.

Check weighing of Chicks of beak trimming was carried out before and on day 7 after beak trimming was calculated from the average daily body weight gain, safety. The results are presented in the table.

Stress deuterocohnia leads to depression of Chicks in the 2nd test and in the control group, the stronger they react to external stimuli, for a long time did not take food and water that ultimately had a negative effect on daily weight gain and preservation. The claimed tool called total calm birds, chickens quickly began to adopt�AMB feed and water. Average daily weight gain after beak trimming in the 1st experimental group were 20.7% higher than in the 2nd test (13,26±0,23 g and is 10.51±0.26 g, respectively), and 22.3% higher than in the control group (13,26±0,23 g and 10.30±0.32, respectively). Safety in the 1st experimental group when applying the claimed funds was also higher by 1% than in the 2nd experimental group and 1.4% higher than the same index in the control group.

Thus, the claimed product has an stressreduction action, at the same time stressreduction effect of the drug ETL-Se-the composition is almost not expressed.

1. Homeopathic medicine with stressreduction and growth-promoting effect, regulating metabolism in young farm animals and poultry, characterized by the fact that it contains Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in specified n�same dilutions in the following ratio, in parts:

Lycopodium clavatum ⌀=D10,004
Podophyllum peltatum ⌀0,003
Acidum arsenicosum ⌀=D20,0001
Phosphorus ⌀=D30,001
Thuja occidentalis ⌀30
Echinacea purpurea ⌀30
Silybum marianum ⌀60
Selenocysteine0,2

2. A compound according to claim 1, characterized in that it is made in the form of microcapsules.

3. A compound according to claim 1, characterized in that it is made in the form of concentrated solution for oral administration.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method for producing an agent for stimulating body cells involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of hydrazine hydrochloride and PEG 400; the prepared mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off; the produced solution is added with hexamethylene tetramine; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances.

EFFECT: producing high-effective, ecologically safe agent by the synergism of colloidal selenium and hexamethylene tetramine on body cell stimulation.

1 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used for the treatment of radiation-thermal injury of an organism. For this purpose a single subcutaneous introduction of bifidumbacterin, irradiated by gamma-rays in a dose of 14.0 Gy, is carried out. Bifidumbacterin is introduced in a dose of 1.43·106 CFU/kg. After that, 10% hypericum oil is applied on the burnt region. Then a 10% hypericum cream is applied after 3-4 days.

EFFECT: method makes it possible to carry out the treatment of combined radiation-thermal injuries in an effective way with the application of available and cheap pharmacotherapeutic means.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: erythrocyte cell medium is added with an aqueous solution of sodium and potassium salts of humic acids prepared on brown coal of leonardite in a dose of 10.0 mg/kg. That is incubated at a temperature of 37°C for 40 minutes before treatment with acidic haemolytic.

EFFECT: invention enables normalising the cell membrane permeability and reducing the damaged cell count under acidic haemolytic.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula (I) X represents a C1-5-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; R1 represents a hydrogen atom or a C1-6-alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6-alkyl group, C2-6-alkenyl group, C3-6-cycloalkyl group, (C3-6-cycloalkyl)-C1-6-alkyl group, halogen-C1-6-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur/gimeracil/oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed.

EFFECT: preparing the intensifier of the antitumour effect.

18 cl, 10 dwg, 10 tbl, 67 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of purification and health improvement of an organism. For this purpose therapeutic starvation for not fewer than 5 days in case of a 7-day programme and for not fewer than 7 days in case of a 9-day programme is carried out. The duration of a recovery period constitutes two days. Food intake is realised nine times per day each day both in the process of therapeutic starvation and in the recovery period. In the period of therapeutic starvation the first food intake includes bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "APITOK" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The second food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The third food intake supposes an intake of bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The fourth food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The fifth food intake consists of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The sixth food intake consists of bee products "APIGRANULES 2" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and one glass of still mineral water. The seventh food intake includes tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The eighth food intake supposes an intake of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The ninth intake of food includes depressant tea, including mint grass, valerian root, fennel seeds, cumin seeds, epilobium or strawberry leaves and one glass of apple-carrot juice. In the recovery period in 1-st, 2-nd, 3-rd, 4-th and 6-th intakes of food the composition of products remains the same as in the process of starvation. For the fifth intake of food the patients take tea black or green with ginger, one teaspoon of honey and vegetable soup. For the seventh intake of food the patients take tea black or green with ginger, "MILK COCKTAIL WITH CHITOSAN". The eighth intake of food includes tea black or green with ginger, one teaspoon of honey, "APICAMPA" cereal. The ninth intake of food for the recovery period includes a baked apple, depressant tea. In addition, a number of procedures are carried out after each food intake during the period of therapeutic starvation and the recovery period. After the first food intake gymnastics "5 Tibetan pearls" is realised. After the second food intake exercises on training apparatuses, procedures of press-therapy, electrolypolysis and myostimulation are realised. After the third food intake exercises of therapeutic physical training or aerobics are performed. After the fourth food intake a rest in form of a walk, a halotherapy session, combined with a session of relaxation therapy are realised. After the fifth food intake a course of strip-plastic is carried out. After the sixth food intake massage by manual application with a peloid-based mixture or manual massage with honey is carried out. After the seventh food intake an infra-red sauna, shower, phytobath with medicinal herbs, honey, ginger, lemon juice is taken. After the eighth food intake a shower is taken.

EFFECT: method ensures effective health improvement of the organism with the preservation of the full value life style and a sense of a comfortable state in the starvation period, reduction of recovery period term after starvation, purification of the organism without loading on the gastrointestinal tract, weight loss, and improvement of the general state and workability of the patients.

3 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, specifically to a fused protein containing a variant of rodostomin, and can be used in medicine. An ανβ3 integrin selective polypeptide consisting of an amino acid sequence SEQ ID NO:1 conjugated on the N terminal by a linker amino acid sequence containing a combination of the amino acids glycine and serine with a variant of a human serum albumin (HSA) with SEQ ID NO:4.

EFFECT: invention enables the higher therapeutic effectiveness in the diseases related to ανβ3 integrin.

12 cl, 14 dwg, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for the correction of the individual's functional state and performance. That is ensured by administering Semax neuroactive peptide in a dose of two drops in each nasal passage. That is followed by the electric current exposure covering a frontal-mastoid region at pulse length 0.2ms, current intensity 0.8mA and pulse train 800Hz for 40 min. The exposure is combined with at least 10 sessions of hyperbaric oxygenation at pressure 1.6 atm.

EFFECT: method provides the rapid and effective increase of performance in sportsmen, military men and individuals involved in the other professions related to significant physical and mental stress by improving the functions of various regions of brain cortex as a result of the selected complex exposure enabling the substantial vasodilatation and maximum tissue oxygenation.

1 tbl

FIELD: medicine.

SUBSTANCE: using a compound representing a bicyclic pyrimidine derivative as Hrf2 transcription factor activators.

EFFECT: compounds of general formula can be used preventively to increase body defences before operations with toxic chemicals and high radiation doses.

3 cl, 7 tbl, 11 ex, 9 dwg

FIELD: medicine.

SUBSTANCE: invention refers to methods for cell and tissue protection against a hypoxic injury and can be used for developing remedies for hypoxic and ischemic injuries. The developed method for protection is based on cell treatment by substances increasing a level of glutathionylation of Na,K-adenosine triphosphatase catalytic subunit that reduces to its activation. The obtained results can be actual for biological research institutions, medical facilities, particularly cardiologic clinics, as well as biotechnological companies for transplantology and tissue engineering.

EFFECT: presented method can be used for research activities aiming at creating the therapeutic agents for relieving tissue injuries, particularly myocardial tissue in hypoxia and hypoxia/reoxygenation.

6 dwg

FIELD: sports.

SUBSTANCE: invention relates to sports medicine and pharmacology, and can be used to increase the overall physical performance of athletes of speed and power sports. To do this, the dietary supplement "Epsorin" is added daily twice a day. At that during the stage of physical training "Epsorin" is taken in for two weeks 30-40 minutes prior to start of the exercise-training process as 10-15 drops per a glass of water; during the period of special physical training it is taken for 10 days 30-40 minutes prior to start of the exercise-training process as 10-15 drops per a glass of water; during the transition period it is taken for 3-5 days 30-40 minutes prior to the training as 5-7 drops per a glass of water; on the day of competitions the dose is increased to 20-30 drops per a glass of water.

EFFECT: method enables to improve the overall physical performance and endurance of athletes due to activation of metabolism and antioxidant systems of the body.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.

EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.

12 cl, 3 tbl, 21 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology. What is presented is the strain Bifidobacterium longum NCIMB 41676 possessing the immunomodulatory action. The above strain is applicable as an anti-infectious probiotic strain. What is also presented is a probiotic formulation containing the above strain and a carrier for oral administration. What is also presented is using the formulation as a cognitive function enhancer for preventing the central nervous system disorders, such as Alzheimer disease, schizophrenia and/or mild cognitive disorders. Alternatively, what is used is the formulation for preventing an inflammation related to obesity, for preventing metabolic disorders related to obesity.

EFFECT: group of inventions provides increasing anti-inflammatory cytokine IL-10 and decreasing proinflammatory cytokines and lipopolysaccharide induced HfkB activity.

37 cl, 16 dwg, 6 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: treating secondary mitochondrial dysfunction in the children suffering an urinogenital pathology is ensured by measuring a pre-therapeutic level of reactive oxygen intermediate (ROI) generation by whole capillary blood leukocytes by luminol-dependent chemoluminescence stimulated by barium sulphate crystals and antioxidant activity (AOA) of serum by chemiluminescence activated by rhodamine B in the presence of ferrous iron ions. If ROI is more than 2.7×105 quantum/sec × 4π, AOA is less than 29 relative units, an energotropic therapy is prescribed in the form of oral administration of 30% carnitine 30 mg/kg/day for one month; thereafter ROI and AOA is re-measured. If ROI is less than 2.7×105 quantum/sec × 4π, AOA is more than 29 relative units, the treatment is terminated; if ROI is more than 2.7×105 quantum/sec × 4π, and AOA is less than 29 relative units, continuing the carnitine therapy is indicated in the same dose for another month.

EFFECT: invention enables optimising the drug-induced treatment of secondary mitochondrial dysfunction in the children with congenital urogenital abnormalities by the individual approach, and grounds prescribing the energotropic therapy and its length.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 3-benzofuranylindol-2-one derivatives substituted in position 3 of formula wherein: R1 means a hydrogen atom; R2, R3, R4 equal or different, found in any accessible position of the phenyl ring, means independently a hydrogen atom or a halogen atom; R5 means (C1-6) alkyl group; n means 1; in the form of the base or acid-additive salt, as well as to a therapeutic agent and a pharmaceutical composition based on the above compounds possessing the ghrelin receptor antagonist activity, and to using this compounds for preparing the therapeutic agent for preventing or treating obesity, diabetes, appetite disorders and overweight.

EFFECT: preparing the therapeutic agent used for preventing or treating obesity, diabetes, appetite disorders and overweight.

8 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of formula

,

wherein: R1 means hydrogen atom; R2, R3, R4 are identical or different, found in any accessible position of phenyl nucleus; they independently mean hydrogen atom and halogen atom; R5 and R6 are identical or different, mean hydrogen atom, (C1-6) alkyl group; R7 means (C1-6) alkyl group; R8 and R9 found in any accessible position of piperazine nucleus, mean hydrogen atom, or (C1-6)alkyl group; at least one of R8 and R9 is differed from H; n means 1; which are present in the form of a base or an acid addition salt, as well as to methods for preparing these compounds, a therapeutic agent or a based pharmaceutical composition for treating obesity, diabetes, appetite disorder and overweight and to therapeutic use of these compounds.

EFFECT: preparing the compounds for treating obesity, diabetes, appetite disorder and overweight and to therapeutic use of these compounds.

10 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition containing copepods fat, and to using this composition for reducing a visceral fat storage. The composition of copepods fat contains wax esters 20-100 wt %, preferentially wax esters 40-85 wt %. The above wax esters consist of monoesters, preferentially mono- or polyunsaturated C16-C22 fatty acids and preferentially monounsaturated C16-C22 fatty alcohols. What is also presented is a preparation containing the above composition.

EFFECT: invention enables preparing the composition used as a drug for preventing or treating abdominal obesity and diabetes mellitus type 2.

22 cl, 3 dwg, 3 tbl

FIELD: veterinary medicine.

SUBSTANCE: preparation for normalisation of lipid peroxidation processes in animals comprises, wt %: 2-ethyl-6-methyl-3-hydroxypyridine succinate 20.0-30.0, ascorbic acid 5.0-7.0, selenium (Se°) 0.3-0.5, polyvinylpyrrolidone 3.0-5.0, water for injection - the rest.

EFFECT: antioxidant effect, prevention of excessive formation of lipid peroxidation products, high efficiency in normalisation of functioning of the system of antioxidant protection of animals and the process of lipid peroxidation, low toxicity and ease of administration.

6 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pyrazolopyridine derivatives of formula (I) , a based pharmaceutical composition, and using them for treating and/or preventing disorders or conditions related to nictonamide adenine dinucleotide phosphatoxidase (NADPH-oxidase), as well as to a method for preparing them and an intermediate of formula (VIII) . In general formula (I), G1 is specified in H; and optionally substituted heteroaryl-C1-C6-alkyl; G2 is specified in H; optionally substituted C1-C6-alkyl; optionally substituted C2-C6-alkenyl; optionally substituted C2-C6-alkinyl; optionally substituted aryl; optionally substituted C1-C6-alkylaryl; optionally substituted aryl-C1-C6-alkyl; optionally substituted heteroaryl; optionally substituted C1-C6-alkylheteroaryl; optionally substituted heteroaryl-C1-C6-alkyl; optionally substituted C2-C6-alkenylaryl; optionally substituted aryl-C2-C6-alkenyl; optionally substituted C2-C6-alkenylheteroaryl; optionally substituted heteroaryl-C2-C6-alkenyl; optionally substituted C3-C8-cycloalkyl; optionally substituted C3-C8-heterocycloalkyl; optionally substituted C1-C6-alkyl-C3-C8-cycloalkyl; optionally substituted C3-C8-cycloalkyl-C1-C6-alkyl; optionally substituted C1-C6-alkyl-C3-C8-heterocycloalkyl and optionally substituted C3-C8-heterocycloalkyl-C1-C6-alkyl; G3 is specified in H; optionally substituted amino; optionally substituted aminoalkyl; optionally substituted aminocarbonyl; optionally substituted alkoxy, optionally substituted alkoxy-C1-C6-alkyl; optionally substituted carbonyl; optionally substituted C1-C6-alkyl; optionally substituted C2-C6-alkenyl; optionally substituted C2-C6-alkinyl; optionally substituted aryl; optionally substituted aryl-C1-C6-alkyl; optionally substituted C1-C6-alkylaryl: optionally substituted heteroaryl; optionally substituted C1-C6-alkylheteroaryl; optionally substituted heteroaryl-C1-C6-alkyl; optionally substituted C2-C6-alkenylaryl; optionally substituted aryl-C2-C6-alkenyl; optionally substituted C2-C6-alkenylheteroaryl; optionally substituted heteroaryl-C2-C6-alkenyl; optionally substituted C3-C8-cycloalkyl; optionally substituted C3-C8-heterocycloalkyl; optionally substituted C1-C6-alkyl-C3-C8-cycloalkyl; optionally substituted C3-C8-cycloalkyl-C1-C6-alkyl; optionally substituted C1-C6-alkyl-C3-C8-hterocycloalkyl and optionally substituted C3-C8-heterocycloalkyl-C1-C6-alkyl; G4 is specified in -NR2-C(O)-R1 and -(CHR3)m-(CH2)n-R4, G5 represents H.

EFFECT: preparing the pharmaceutical composition for treating and/or preventing the disorders and conditions related to nictonamide adenine dinucleotide phosphatoxidase.

16 cl, 3 tbl, 87 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical industry, particularly to compositions for treating and/or preventing obesity. The composition contains the peptide compound Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His in water containing a salt solution in the physiologically acceptable concentration. A therapeutic agent containing the above composition can be presented in the form of spray/drops applicable for nasal, subglossal or oral administration. A dosage form of the nasal or subglossal spray/drops, as well as oral film provides ease of administration and makes it applicable by the patient in need of treating and/or preventing obesity.

EFFECT: compositions and agents are effective for treating obesity.

45 cl, 4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent containing activated-potentiated forms of anti-histamine, anti-tumour necrosis factor alpha (anti-TNF - α) and anti-S-100 brain specific antibodies is administered.

EFFECT: treating functional bowel disorders by ensuring the spasmolytic action and normalising the motor-evacuation function of the intestine.

11 cl, 4 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method for producing an agent inhibitory the tumour cell growth, involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of aqueous solution of hydrazine hydrochloride and PEG 400; the produced mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off in a rotary evaporator; the produced solution is added with silymarin dissolved in Solufor with dialysis against distilled water; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances.

EFFECT: agent produced by the given method possesses high inhibitory action on the tumour cell growth.

4 dwg, 2 tbl, 2 ex

Up!